Eloxx Pharmaceuticals, an Israel-based developer of therapies aimed at genetic diseases, raised $8m from investment firm LSP on Wednesday to close its series C round at $38m.
The initial $30m tranche was closed last month and led by Pontifax, with participation from medical diagnostics technology maker Opko Health, Korea Investment Partners, DSC Investments, the Quark Venture and GF Securities-managed Global Health Science Fund and angel investor Phil Frost.
The series C round comes ahead of a reverse merger of Eloxx with…